/PASG

PASG Stock - Passage Bio, Inc.

Q: What is the analyst price target for PASG?

Analyst price target information is not currently available for PASG.

Q: What is PASG's market cap?

Market capitalization information is not currently available for PASG.

Healthcare|Biotechnology|NASDAQ

$9.59+1.59%

+$0.15 (+1.59%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+-37.4%upside

Target: $6.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for PASG

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.86

52W High$20.20

52W Low$5.12

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	$-3,721,000	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-70,400,000	$-100,136,000	$-138,394,000	$-185,729,000	$-112,902,000
Net Income	$-64,767,000	$-102,062,000	$-136,125,000	$-185,386,000	$-112,232,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-21.44	$-37.29	$-50.00	$-69.51	$-57.80

Company Overview

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

2 Bullish0 Neutral/Bearish

Price Targets

Average Target

↓ 42.6% Downside

Now

Low

Average

High

Based on 2 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
November 29th 2024	Wedbush	Resumed	Outperform	$4← $3
September 3rd 2024	Rodman & Renshaw	Initiation	Buy	$7

Earnings History & Surprises

PASG

Beat Rate

61%

Last 18 quarters

Avg Surprise

+3.0%

EPS vs Estimate

Beats / Misses

11/7

Last 12 quarters

Latest EPS

$-2.44

Q4 2025

EPS Surprise History

Q1 24

+26.8%

$-0.30vs$-0.41

Q2 24

+18.9%

$-0.30vs$-0.37

Q3 24

+16.1%

$-0.26vs$-0.31

Q4 24

-34.8%

$-0.31vs$-0.23

Q1 25

+4.8%

$-0.20vs$-0.21

Q2 25

-4.2%

$-5.00vs$-4.80

Q3 25

+26.0%

$-2.96vs$-4.00

Q4 25

+7.6%

$-2.44vs$-2.64

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 11, 2026	—	—	—	—
Q1 2026	Mar 3, 2026	$-2.19	—	—	—
Q4 2025	Nov 10, 2025	$-2.64	$-2.44	+7.6%	✓ BEAT
Q3 2025	Aug 12, 2025	$-4.00	$-2.96	+26.0%	✓ BEAT
Q2 2025	May 13, 2025	$-4.80	$-5.00	-4.2%	✗ MISS
Q1 2025	Mar 4, 2025	$-0.21	$-0.20	+4.8%	✓ BEAT
Q4 2024	Nov 13, 2024	$-0.23	$-0.31	-34.8%	✗ MISS
Q3 2024	Aug 8, 2024	$-0.31	$-0.26	+16.1%	✓ BEAT
Q2 2024	May 14, 2024	$-0.37	$-0.30	+18.9%	✓ BEAT
Q1 2024	Mar 4, 2024	$-0.41	$-0.30	+26.8%	✓ BEAT
Q4 2023	Nov 13, 2023	$-0.47	$-0.49	-4.3%	✗ MISS
Q3 2023	Aug 7, 2023	$-0.48	$-0.44	+8.3%	✓ BEAT
Q2 2023	May 11, 2023	$-0.49	$-0.63	-28.6%	✗ MISS
Q1 2023	Mar 6, 2023	$-0.48	$-0.50	-4.2%	✗ MISS
Q4 2022	Nov 10, 2022	$-0.75	$-0.49	+34.7%	✓ BEAT
Q3 2022	Aug 4, 2022	$-0.78	$-0.73	+6.4%	✓ BEAT
Q2 2022	May 16, 2022	$-0.88	$-0.79	+10.2%	✓ BEAT
Q1 2022	Mar 3, 2022	$-0.84	$-0.93	-10.7%	✗ MISS
Q4 2021	Nov 4, 2021	$-0.80	$-0.77	+3.8%	✓ BEAT
Q3 2021	Aug 5, 2021	$-0.73	$-0.90	-23.3%	✗ MISS